Regenxbio Inc (NASDAQ: RGNX) is -46.35% lower on its value in year-to-date trading and has touched a low of $8.53 and a high of $28.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RGNX stock was last observed hovering at around $11.14 in the last trading session, with the day’s loss setting it -1.51%.
Currently trading at $9.63, the stock is -1.85% and -8.27% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.28 million and changing -13.55% at the moment leaves the stock -32.74% off its SMA200. RGNX registered -49.69% loss for a year compared to 6-month loss of -39.77%. The firm has a 50-day simple moving average (SMA 50) of $10.498 and a 200-day simple moving average (SMA200) of $14.31765.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.15% gain in the last 1 month and extending the period to 3 months gives it a -22.84%, and is -13.71% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.22% over the week and 7.57% over the month.
Regenxbio Inc (RGNX) has around 344 employees, a market worth around $412.45M and $84.33M in sales. Profit margin for the company is -283.19%. Distance from 52-week low is 12.83% and -66.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-57.85%).
with sales reaching $23.45M over the same period.The EPS is expected to grow by 21.64% this year, but quarterly earnings will post -3.73% year-over-year. Quarterly sales are estimated to grow 5.56% in year-over-year returns.
Regenxbio Inc (RGNX) Top Institutional Holders
271.0 institutions hold shares in Regenxbio Inc (RGNX), with institutional investors hold 99.62% of the company’s shares. The shares outstanding are 49.55M, and float is at 44.84M with Short Float at 10.95%. Institutions hold 92.26% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 8.61 million shares valued at $100.73 million. The investor’s holdings represent 18.8252% of the RGNX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 5.11 million shares valued at $59.83 million to account for 11.1818 of the shares outstanding. The other top investors are REDMILE GROUP, LLC which holds 4.57 million shares representing 9.9924% and valued at over $53.47 million, while JPMORGAN CHASE & CO holds 6.5871 of the shares totaling 3.01 million with a market value of $35.25 million.
Regenxbio Inc (RGNX) Insider Activity
The most recent transaction is an insider sale by KARABELAS ARGERIS N, the company’s Director. SEC filings show that KARABELAS ARGERIS N sold 10,000 shares of the company’s common stock on Oct 01 ’24 at a price of $10.11 per share for a total of $0.1 million. Following the sale, the insider now owns 11286.0 shares.
Regenxbio Inc disclosed in a document filed with the SEC on Sep 03 ’24 that KARABELAS ARGERIS N (Director) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Sep 03 ’24 and was made at $11.56 per share for $0.12 million. Following the transaction, the insider now directly holds 11286.0 shares of the RGNX stock.
Still, SEC filings show that on Aug 01 ’24, KARABELAS ARGERIS N (Director) disposed off 10,100 shares at an average price of $13.51 for $0.14 million. The insider now directly holds 11,286 shares of Regenxbio Inc (RGNX).
